Payment overview · 2025
General Payments
$699.34
37 reported records · 17 companies
Healthcare provider profile · identity verified
T. Mark Stanfield, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MADISONVILLE, KY · NPI 1689771396
Verified facts
What the public records show
CMS Open Payments records show T. Mark Stanfield, MD received $699.34 in general payments during 2025 across 37 reported records.
Novartis Pharmaceuticals Corporation accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $115.21 | 16.5% | 7 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $104.78 | 15.0% | 6 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $69.06 | 9.9% | 4 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $65.42 | 9.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.00 | 6.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.54 | 5.5% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $36.85 | 5.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.38 | 5.1% | 2 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $31.80 | 4.5% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $27.77 | 4.0% | 1 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $22.05 | 3.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $21.48 | 3.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.25 | 2.8% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $18.45 | 2.6% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $16.32 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.76 | 2.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.22 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $699.34 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $115.21 | 7 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $104.78 | 6 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $65.42 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $65.42 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.00 | 3 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $37.11 | 2 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.38 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $34.64 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $27.77 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $27.77 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| PICO 7 Normalized: pico 7 |
Device | Smith+Nephew, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| Pico 14 Normalized: pico 14 |
Device | Smith+Nephew, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| Fluency Endovascular Stent Graft Normalized: fluency endovascular stent graft |
Device | Bard Peripheral Vascular, Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 88 | 28 |
| Cilostazol | Cilostazol | 41 | 11 |
| Mupirocin | Mupirocin | 24 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 22 |
| Xarelto | Rivaroxaban | 22 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $699.34 · 37 records | Novartis Pharmaceuticals Corporation | AVEIR, CLOTTRIEVER BOLD CATHETER, ELUVIA, ENDOCROSS Device, ENTRESTO, Fluency Endovascular Stent Graft, KEYTRUDA, Kerecis GraftGuide, Kerecis SurgiClose, LEQVIO, LifeVest, Ohtuvayre, PICO 7, Pico 14, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, REPATHA, RotarexS 6 F x 135 cm, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, TAGRISSO, TEZSPIRE, TRELEGY ELLIPTA, TREO ABDOMINAL STENT-GRAFT SYSTEM, Torus Stent Graft System, Tyvaso, Venovo | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error